שווי פעילות לרווח לפני ריבית, מסים ופחת Gossamer Bio (GOSS)

The absence of commercial sales and a reliance on grants create high risks, as confirmed by the EV/EBITDA trajectory of Gossamer Bio, Inc. (GOSS). The value of 0.00 represents the current level of this metric. The business relies on an asset-light model with R&D based in the US, outsourcing drug manufacturing to contractors. All clinical trials have been fully delegated to external partners, which minimizes the internal costs of Gossamer Bio, Inc. (GOSS).

The EV/EBITDA multiple compares the total enterprise value, including debt, with operating profit before taxes and depreciation, allowing for an assessment of the asset's real value regardless of the financing structure. By analyzing the EV/EBITDA valuation multiple for capital-intensive businesses, an investor can identify whether shares of Gossamer Bio, Inc. (GOSS) are overvalued, given that its pulmonary hypertension developments are protected by humanitarian status and stable global supplies.